We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,523 hedge funds and large institutions have $63.3B invested in Bristol-Myers Squibb in 2016 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 663 increasing their positions, 548 reducing their positions, and 147 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 663 | Existing positions reduced: 548

3.14% less ownership

Funds ownership: 73.94%70.8% (-3.1%)

3% less funds holding

Funds holding: 1,5771,523 (-54)

17% less call options, than puts

Call options by funds: $1.15B | Put options by funds: $1.38B

25% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 147

30% less capital invested

Capital invested by funds: $90.9B → $63.3B (-$27.6B)

55% less funds holding in top 10

Funds holding in top 10: 11049 (-61)

Holders
1,523
Holders Change
-54
Holders Change %
-3.42%
% of All Funds
40.62%
Holding in Top 10
49
Holding in Top 10 Change
-61
Holding in Top 10 Change %
-55.45%
% of All Funds
1.31%
New
110
Increased
663
Reduced
548
Closed
147
Calls
$1.15B
Puts
$1.38B
Net Calls
-$227M
Net Calls Change
-$366M
Name Holding Trade Value Shares
Change
Change in
Stake
SGA
1526
Sustainable Growth Advisers
Connecticut
-$103M -1,402,482 Closed
SGAM
1527
Smith Group Asset Management
Texas
-$72.9M -990,710 Closed
Voloridge Investment Management
1528
Voloridge Investment Management
Florida
-$69.4M -942,911 Closed
PHS
1529
PFM Health Sciences
California
-$33.4M -519,722 Closed
Point72 Asset Management
1530
Point72 Asset Management
Connecticut
-$34.6M -470,600 Closed
ASC
1531
Atalanta Sosnoff Capital
New York
-$33.5M -455,918 Closed
AC
1532
Ascend Capital
California
-$27.2M -370,293 Closed
WI
1533
Wafra Inc
New York
-$25.4M -344,852 Closed
BCM
1534
Barometer Capital Management
Ontario, Canada
-$22.4M -304,642 Closed
Artisan Partners
1535
Artisan Partners
Wisconsin
-$18.7M -253,896 Closed
HM
1536
HealthCor Management
New York
-$15.6M -211,940 Closed
BIM
1537
BRC Investment Management
Colorado
-$15.5M -210,189 Closed
Mackenzie Financial
1538
Mackenzie Financial
Ontario, Canada
-$13.7M -186,335 Closed
LOAMS
1539
Lombard Odier Asset Management (Switzerland)
Switzerland
-$10.7M -145,118 Closed
MAM
1540
Mark Asset Management
New York
-$7.67M -104,263 Closed
MIFH
1541
Migdal Insurance & Financial Holdings
Israel
-$7.54M -101,970 Closed
SCM
1542
Sandler Capital Management
New York
-$7.36M -100,000 Closed
AIM
1543
Artemis Investment Management
United Kingdom
-$7.25M -98,500 Closed
MME
1544
Meag Munich Ergo
Germany
-$6.97M -94,882 Closed
MSU
1545
Mizuho Securities USA
New York
-$6.79M -92,300 Closed
PVI
1546
Pura Vida Investments
New York
-$6.34M -86,250 Closed
GLAM
1547
Gardner Lewis Asset Management
Pennsylvania
-$5.91M -80,348 Closed
FLII
1548
First Long Island Investors
New York
-$5.74M -78,000 Closed
EA
1549
Euclid Advisors
Connecticut
-$4.68M -63,647 Closed
SGH
1550
Sivik Global Healthcare
Connecticut
-$4.04M -55,000 Closed

BMY Hedge Fund Activity: Q3 2016 in Review

1,523 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2016, worth a combined $63.3B — down 30% from $90.9B a quarter earlier.

Sellers outnumbered buyers: 147 funds closed out of BMY and 110 opened new positions — a net loss of 37 holders — while 548 trimmed existing stakes and 663 added.

The largest buyer was Wellington Management Group, adding an estimated $437M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.74B.

  • 1,523 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2016, down from 1,577 in Q2 2016.
  • Funds reported $63.3B of Bristol-Myers Squibb stock for Q3 2016, down 30% quarter-over-quarter.
  • 110 funds opened new Bristol-Myers Squibb positions in Q3 2016 and 147 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2016 was Wellington Management Group, an estimated $437M added.
  • The largest Bristol-Myers Squibb seller in Q3 2016 was T. Rowe Price Associates, an estimated $1.74B sold.

Based on aggregated 13F filings for Q3 2016.